450 related articles for article (PubMed ID: 28042144)
21. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
22. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Winter GE; Buckley DL; Paulk J; Roberts JM; Souza A; Dhe-Paganon S; Bradner JE
Science; 2015 Jun; 348(6241):1376-81. PubMed ID: 25999370
[TBL] [Abstract][Full Text] [Related]
23. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
25. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
26. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
Front Oncol; 2021; 11():753119. PubMed ID: 34733788
[TBL] [Abstract][Full Text] [Related]
27. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
[TBL] [Abstract][Full Text] [Related]
28. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
30. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Lim SL; Damnernsawad A; Shyamsunder P; Chng WJ; Han BC; Xu L; Pan J; Pravin DP; Alkan S; Tyner JW; Koeffler HP
Haematologica; 2019 Jun; 104(6):1209-1220. PubMed ID: 30606790
[TBL] [Abstract][Full Text] [Related]
31. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
32. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
Lu Q; Ding X; Huang T; Zhang S; Li Y; Xu L; Chen G; Ying Y; Wang Y; Feng Z; Wang L; Zou X
Am J Transl Res; 2019; 11(9):5728-5739. PubMed ID: 31632543
[TBL] [Abstract][Full Text] [Related]
33. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
DeMars KM; Yang C; Castro-Rivera CI; Candelario-Jalil E
Biochem Biophys Res Commun; 2018 Feb; 497(1):410-415. PubMed ID: 29448097
[TBL] [Abstract][Full Text] [Related]
34. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
He Y; Ju Y; Hu Y; Wang B; Che S; Jian Y; Zhuo W; Fu X; Cheng Y; Zheng S; Huang N; Qian Z; Liu J; Zhou P; Gao X
J Control Release; 2023 Feb; 354():155-166. PubMed ID: 36538950
[TBL] [Abstract][Full Text] [Related]
35. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
36. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.
Vartak R; Saraswat A; Yang Y; Chen ZS; Patel K
Pharm Res; 2022 Nov; 39(11):2745-2759. PubMed ID: 35146591
[TBL] [Abstract][Full Text] [Related]
38. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
39. Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable'
Saraswat A; Patki M; Fu Y; Barot S; Dukhande VV; Patel K
Nanomedicine (Lond); 2020 Aug; 15(18):1761-1777. PubMed ID: 32698663
[No Abstract] [Full Text] [Related]
40. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
